Discrepant findings have been reported regarding an association of the apolipoprotein E (APOE) gene with the clinical course of multiple sclerosis (MS). To resolve these discrepancies, we examined common sequence variation in six candidate genes residing in a 380-kb genomic region surrounding and including the APOE locus for an association with MS severity. We genotyped at least three polymorphisms in each of six candidate genes in 1540 Caucasian MS families (729 single-case and multiple-case families from the United States, 811 single-case families from the UK). By applying the quantitative transmission/ disequilibrium test to a recently proposed MS severity score, the only statistically significant (P ¼ 0.003) association with MS severity was found for an intronic variant in the Herpes Virus Entry Mediator-B Gene (PVRL2). Additional genotyping extended the association to a 16.6 kb block spanning intron 1 to intron 2 of the gene. Sequencing of PVRL2 failed to identify variants with an obvious functional role. In conclusion, the analysis of a very large data set suggests that genetic polymorphisms in PVRL2 may influence MS severity and supports the possibility that viral factors may contribute to the clinical course of MS, consistent with previous reports.
Introduction
Multiple sclerosis (MS) is the most common autoimmune disorder of the central nervous system (CNS) in young adults, and affects females two to three times more frequently than males. The lifespan of affected individuals is only slightly shortened, but the impact of the disease on the quality of life for patients and on national healthcare systems is substantial. MS is characterized by inflammation, myelin loss, gliosis, varying degrees of axonal pathology and progressive neurological dysfunction. 1 The natural history of MS is highly variable with no known predictors of disease progression. In Caucasian populations, 20-40% of patients have a benign disease course over extended periods of time, 50% enter a secondary-progressive phase after about 5-15 years from disease onset, and the remaining 10-30% of patients are diagnosed with primary progressive MS. 2, 3 A very small proportion of patients presents with a progressiverelapsing form of the disorder. A large body of research supports genetic influences on both susceptibility to, and progression of, MS. [4] [5] [6] However, the relationship between genotype and phenotype is clearly complex, and a number of different polymorphic genes with individually small or moderate effects are believed to act together or independently to increase the risk of being affected with MS, or to exacerbate the course of the disease.
Several previous studies suggested that the apolipoprotein E gene (APOE, MIM 107741) on chromosome 19q13, a major lipid carrier protein in the brain and CNS, may be a modifier of MS progression. [7] [8] [9] [10] [11] [12] [13] [14] [15] Specifically, the APOE-4 allele was associated with a more severe disease course, whereas carriers of the APOE-2 allele appeared more likely to have a milder form of MS. However, a similar number of studies failed to replicate this association. [16] [17] [18] [19] [20] [21] [22] [23] There is moderate evidence supporting a susceptibility locus on chromosome 19; however, this locus is likely to be more distal to APOE than the region considered here. 24, 25 The APOE gene is a plausible candidate modifier gene, owing to its involvement in other neurodegenerative disorders, including Alzheimer's disease, 26 Parkinson disease 27 and amyotrophic lateral sclerosis. 28 APOE has been associated with regeneration of axons and myelin after lesions in central and peripheral nervous tissue, 29 and has immunomodulatory and antioxidant effects. 30 A more severe clinical course of experimental autoimmune encephalomyelitis in apoE-knockout mice has also been reported. 31 Despite a plausible functional involvement of the APOE gene in MS progression, it is possible that an observed association of a particular APOE allele is actually due to linkage disequilibrium (LD) with a causal variant at a nearby locus. This could explain the inconsistency of results across studies, as the level of LD might vary in different data sets. A comprehensive examination of sequence variants in MS candidate genes immediately surrounding the APOE locus using a very large patient data set has not yet been performed, but is crucial for resolving the discrepant findings reported for this region. Here, we present results of a comprehensive analysis of sequence variation in six candidate genes located in the genomic region of interest, using one of the largest collections of clinically well-characterized MS patients and their relatives.
Results

Marker characterization
All genotyped single-nucleotide-polymorphisms (SNPs) were in Hardy-Weinberg equilibrium (HWE, PX0.03) in unrelated affected and unaffected genotyped individuals. Allele frequencies at all SNPs were very similar in US and UK probands (P40.05 for w 2 -tests), and the average allele frequency difference was only 1.2%. The F ST value was 0.0002, which is similar to that seen in the homogeneous Icelandic population. 32 A Haploview plot of the LD pattern in the region, including both our initial set of 21 genotyped markers and the additional nine SNPs subsequently genotyped in the PVRL2 gene (poliovirus receptor-related 2, herpesvirus entry mediator B, MIM 600798), is shown in Figure 1 . As previously noted 33 and confirmed by the publicly available HapMap data, this figure illustrates a general lack of long-range LD in the 380 kb region immediately surrounding APOE. Of particular interest was the fact that neither of the two functional APOE SNPs that define the three protein isoforms was in pairwise LD with SNPs in PVRL2. However, pairwise D 0 -values of 0.8 were observed for two pairs of SNPs, each of which included an APOE promoter SNP and a variant in PVRL2 (
Family-based association analysis of MS severity The Monks-Kaplan quantitative transmission/disequilibrium test (MK-QTDT) detected an influence of genotypes at rs394221 in PVRL2 on variation in MS severity scores (MSSS), which was statistically significant based on Nyholt's correction for multiple testing (P ¼ 0.003). This SNP was the only one of the initially genotyped SNPs that showed significant evidence for an association with MS severity. Our data set provided no support for an association with either of the previously examined functional APOE alleles (P ¼ 0. . As the number of informative multiplex families was limited, this information simply provides a description of the observed pattern rather than a formally stratified statistical analysis. The evidence for an association of MS severity with genotypes at rs394221 was not substantially modified by DR2 carrier status (as defined in the Patients and methods section), based on subgroup analyses of DR2 þ and DR2À families (data not shown).
As expected on the basis of LD between rs394221 and flanking markers, a haplotype analysis extended the association of PVRL2 with MSSS scores to a 16.6 kb block within the gene. A global P-value of 0.03 was obtained for the SNP combination rs2972566-rs394221, primarily owing to a positive association of MSSS values with haplotype G-A (estimated frequency 54.3%) and a negative association with haplotype C-G (estimated frequency 15.8%). A global P-value of 0.009 was obtained for the SNP combination rs394221-rs4803766, primarily owing to a positive association with haplotype A-G (estimated frequency 56.0%) and a negative association with haplotype G-A (estimated frequency 42.2%). Thus, the haplotype analysis did not provide stronger evidence for association than the single-locus analysis.
Sequencing identified a total of 93 SNPs in the 37.5 kb of genomic PVRL2 sequence that were analyzed (Supplementary Table 1 online only). Of these, 26 were novel SNPs identified in this study. No non-synonymous coding changes or other obvious functional variants were identified. A common novel SNP in intron 1 (G50045884T) was genotyped in the entire study population, but did not show evidence for association with MS severity (P ¼ 0.19). Figure 3 shows the PVRL2 exonintron structure, indicating the SNPs genotyped in the entire study population by arrows.
Discussion
To examine whether sequence variants in a previously implicated genomic region were associated with MS severity, we have analyzed six candidate genes in a 380 kb region surrounding the APOE locus on chromosome 19q13 in a very large MS patient data set. We applied the quantitative transmission/disequilibrium test (QTDT), family-based to the global MSSS, a statistically powerful measure of MS severity based on clinical data from all fully evaluated MS patients. Our results did not support an association of MS severity with APOE alleles, contrary to several earlier studies but consistent with a recent meta-and pooled-analysis of over 4000 MS patients. 35 Instead, we detected marginally significant evidence for an association of several common variants in a 16.6 kb block spanning intron 1 to intron 2 of the PVRL2 gene with MSSS scores. This observation supports the possibility that viral factors may contribute to the clinical course of MS in a subset of patients and/or families. However, at this point, it is unknown whether any of these sequence variants have functional consequences on the protein coded by PVRL2, which is known as nectin-2, HVEB or CD112.
Although virtually all studies of the 19q13 region in MS have focused exclusively on the APOE gene, one other group recently examined the PVR and PVRL2 genes, 34 albeit in only a small number (n ¼ 53) of MS families. The authors did not observe expression differences of either gene in peripheral blood monocyte cells of MS patients and healthy controls. They failed to identify any obvious functional sequence polymorphisms in the promoter and exonic regions of PVRL2. An intronic polymorphism also typed in our study (rs416041) was not associated with MS disease type (relapsing-remitting, secondary progressive, or primary progressive) in their data set. The authors did not use the MSSS as a measure of disease severity. A previous study 14 suggested that an APOE association with MS severity may be limited to female patients. Although the MK-QTDT test statistic was larger when only MSSS data from female patients in the combined data set were analyzed (T ¼ 2.35, P ¼ 0.02), compared to an analysis of only male patients (T ¼ 1.83, P ¼ 0.07), the same allele at rs394221 was associated with a higher average severity in both groups, and the numeric difference is likely due to the larger sample size of female patients. Therefore, our data do not support gender-specific effects of PVRL2 on MS severity.
Strengths of our study included a very large sample size of MS patients with available information on disease severity, and a comprehensive evaluation of sequence variation in MS candidate genes including and immediately surrounding the previously implicated APOE gene. The main limitation was a cross-sectional, rather than longitudinal, assessment of disease severity by a combination of Expanded Disability Status Scale (EDSS) scores and disease duration. However, we believe that the MSSS is currently the most reliable instrument for estimating the actual severity of the disease. Our study has captured the majority of common sequence variation in the region of interest. HapMap genotype data support an absence of long-range LD in this region, suggesting that, it is unlikely for polymorphisms outside our genotyped region to be in LD with APOE alleles, and thus potentially responsible for the MS associations reported by earlier studies.
It is currently unknown whether the MS-associated PVRL2 polymorphisms reported here have any functional consequences. It is possible that they are in LD with as yet uncharacterized sequence variants that may modify the functionally important V domain of nectin-2, which acts as the viral glycoprotein D receptor for herpes simplex virus HSV-2 and variant forms of HSV-1. 36 Alternatively, the intronic region of interest may harbor variants that regulate gene splicing. Splicing regulation is believed to be a major genetic modifier of complex human diseases 37, 38 and has been proposed as the mechanism by which the CTLA4 gene may influence several autoimmune disorders, including Graves' disease, autoimmune hypothyroidism and type I diabetes. 39 The ability of viral infections to induce demyelinating CNS diseases may depend specifically on the resistance of human oligodendrocytes to viral attacks. Oligodendrocytes are the myelin-forming cells of the CNS and likely the initial target of MS onset or relapses. Transmission of HSV via bodily fluids usually causes a primary infection, which may lead to symptoms of oral (HSV-1) or genital (HSV-2) herpes, or remain asymptomatic. After resolution of the primary infection, a latent host infection can be established 40 and the virus may be reactivated later in life. The molecular mechanisms underlying HSV latency and reactivation in the CNS are poorly understood but are believed to be controlled by the immune system. 41, 42 Interestingly, the presence of actively replicating HSV-1 mRNA has been associated with acute clinical attacks in patients with relapsingremitting MS. 43 This suggests that HSV-1 reactivation may exacerbate the clinical presentation of MS, possibly by virus-induced demyelination. 44 Consistent with this observation and the results reported here, recent experimental studies have shown that human oligodendrocytelike cells are highly susceptible to HSV-1 infection, 45 and that differences in virus-host cell interactions, and hence HSV-1 susceptibility, are probably genetically determined. 46 Interestingly, another member of the Herpesviridae family, human herpesvirus 6 , has also been associated with MS. 47 In summary, our study suggests that sequence variants in a 16.6 kb block spanning intron 1 to intron 2 of PVRL2 may influence the severity of MS in a subset of patients. It is currently unknown whether these variants, or others in LD with them, alter the functionality of the viral receptor region, or affect gene splicing. If functional consequences of PVRL2 polymorphisms on MS-relevant molecular mechanisms could be demonstrated, this would greatly increase the evidence for a contribution of latent viral infections to the natural history of MS and rs1871047 G50045884T rs6857 Figure 3 Exon-intron structure of PVRL2. Shaded boxes are 5 0 and 3 0 UTR, respectively. White boxes are exons, numbered 1-6a for isoform 1 and 1-6b-9 for isoform 2.
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S Schmidt et al may suggest novel avenues for MS diagnosis and treatment.
Patients and methods
Study population and measure of MS severity
The US data set consisted of 729 stringently ascertained families of MS patients (542 single-case and 187 multiplecase (multiplex) families) comprising 2874 sampled individuals, of whom 1098 were affected with MS. All known ancestors were non-Hispanic whites of European descent. Diagnostic criteria and ascertainment protocols have been summarized elsewhere. [48] [49] [50] Positive family histories were investigated by direct contact with other family members, requests for medical records, and by clinical examination, laboratory testing or paraclinical studies (MRI scanning and evoked-response testing). All affected family members were examined or had their medical records reviewed by one of the authors (SLH). The UK data set consisted of 811 Caucasian MS patients and one or both of their parents, for a total of 2327 sampled individuals. Patients were diagnosed according to the same clinical criteria, as described previously, 51 for a total of 1909 patients with clinically definite MS from the combined data set of 1540 families. All study protocols were approved by the appropriate Institutional Review Boards and all individuals provided informed consent before participating in the study.
Different measures of MS severity have been used in previous genetic association studies, which likely contributed to the discrepant findings reported for the APOE gene. The MSSS was recently proposed as a novel method for comparing disease progression of a group of patients using the most recent clinical assessment data. 52 A simulation study conducted by the authors demonstrated substantially better power of the MSSS to detect effects on MS severity, compared to either a categorical analysis 13, 50 or the use of a progression index (ratio of EDSS and disease duration) that assumes a linear progression of disability over time. The MSSS essentially describes the decile of the EDSS score 53 within the range of patients from a large reference population who have had MS for the same number of years, with disease duration defined as age at most recent clinical examination minus age at onset of MS symptoms. For the analysis presented here, we used the 'global MSSS' derived from a large reference population of 9892 European MS patients. 52 As EDSS ratings for the US data were only available as five distinct categories (o3, 3-5.5, 6.0, 6.5, X7.0), we averaged across the corresponding half-step categories of EDSS for the given disease duration to calculate the MSSS. The UK data were available in the same half-step categories used in the derivation of the global MSSS. 52 Of the 1909 patients with clinically definite MS, complete information on EDSS scores and disease duration was available for 1752 individuals (92%) from 1505 families (184 US multiplex, 519 US single-case, 802 UK single-case). A clinical and demographic description of these patients is shown in Table 1 . The US and UK study populations were clinically very similar, as was the proportion of carriers of the MSassociated HLA-DRB1*1501 (DR2) allele (US: 60.5%, UK: 64.4%). Thirty-one (16.8%) of the US multiplex families included only one patient for whom the MSSS could be calculated, 94 (51.1%) included two, 41 (22.3%) included three and 18 (9.8%) included four or more such patients.
SNP selection and genotyping methods
Genomic DNA was extracted from whole blood using standard procedures as described elsewhere. 54 Public domain databases (Japanese JSNP, http://snp.ims.utokyo.ac.jp, NCBI's dbSNP, http://www.ncbi.nlm.nih.-gov/SNP/) and SNPSelector 55 were used to identify SNPs from the following five plausible MS candidate genes that were located 260 kb centromeric and 120 kb telomeric of APOE: PVR (poliovirus receptor, MIM 173850), CBLC (Cas-Br-M (murine) ecotropic retroviral transforming sequence c, MIM 608453), PVRL2 (polio- 56, 57 CBLC and RELB were selected because they are believed to regulate the NF-kB cascade, which has previously been implicated in MS, [58] [59] [60] and PVR and PVRL2 were of particular interest because viral infections have long been suspected to be environmental triggers of MS. 43, [61] [62] [63] Genotype data from the HapMap project (http:// www.hapmap.org) were used for SNP validation and for visual inspection of the LD structure in this region of the genome. All SNP genotypes, including the two SNPs in exon 4 of the APOE gene that define the three functional APOE alleles commonly referred to as e2, e3 and e4, were generated by the TaqMan allelic discrimination assay on an ABI7900HT genotyping platform. TaqMan primers and probes were designed for genotyping at least three common (MAFX5%) SNPs in each of the six candidate genes (including APOE), using the Assay-on-Demand or Assay-by-Design service from Applied Biosystems (Foster City, CA, USA). A total of 22 SNPs (21 markers, counting the two SNPs that define the three functional alleles of APOE as one marker) were generated initially, including at least two HapMap-genotyped SNPs per gene ( Table 2 ). Duplicate quality control samples were 64 for analysis. Laboratory personnel were blinded to pedigree structure, affection status and location of quality control samples. All SNPs were required to have at least 90% genotyping efficiency.
After observing a statistically significant association of the initially genotyped SNP rs394221 in PVRL2 with MS severity, we carried out de novo SNP identification and validation by sequencing PVRL2 in 20 individuals from the lowest and 20 individuals from the highest MSSS decile. In total, 37.5 kb (77.3%) of genomic sequence from the 48.5 kb PVRL2 gene was generated from all exonic and intronic regions of the two isoforms of PVRL2 (six exons in the short, nine exons in the long isoform), with the exception of exon 1 and intronic regions that were not amenable to primer design. In addition, we sequenced regions of multispecies sequence conservation 5 0 of PVRL2 and within intron 1 to identify candidate SNPs in putative regulatory domains. Nine additional PVRL2 SNPs were genotyped in the entire study population.
Statistical methods
Genotype error checking and marker characterization. Marker genotypes causing unresolvable Mendelian inconsistencies, as identified by the program PEDCHECK, 65 and those implying greater-than-expected recombination rates given the small physical distances between SNPs, as identified by the MERLIN program, 66 were eliminated from the analysis. All SNPs were tested for HWE in samples of unrelated affected (one affected from each family) and unaffected (one unaffected from each family, if available) individuals, using an exact test implemented in the GDA program. 67 SNP allele frequencies in US and UK probands were compared with w 2 -tests, and Wright's F statistic (F ST ) 68 was computed using SAS (version 8.02, SAS Institute Inc., Cary, NC, USA). F ST measures the extent to which observed heterozygosity deviates from the expected value if all probands had the same genetic background. A comprehensive picture of the LD structure in the region was generated with the Haploview program, 69 using a single affected genotyped individual from each of the 1540 MS families.
Family-based association analysis of MS severity. The family-based MK-QTDT, 70 which is implemented in the QTDT program, 71 was used to examine whether alleles at any of the 21 initially genotyped markers were associated with MSSS scores. A modified Nyholt correction was used to adjust for multiple testing, taking into account the LD relationships between the SNPs. 72, 73 Owing to the well-known effect of the MS-associated HLA-DRB1*1501 (DR2) allele, analyses were also conducted separately in a family subgroup defined as 'DR2 positive (DR2 þ )', which included single-case families whose proband carried at least one DR2 allele and multiplex families in which all affected relatives were DR2 carriers, and another subgroup defined as 'DR2 negative (DR2À)', which included single-case families with non-carrier probands and multiplex families without any affected DR2 carriers. To identify the subset of MS families that contributed positively to significant MK-QTDT results, we used SAS to compute the family-specific MK score based on the statistics T QP and T QS described in the original report. 70, 74 Selected haplotype association tests with the FBAT package, 75, 76 using the hbat -e program command (http://www.biostat.harvard.edu/~fbat/ fbat.htm), were performed to follow up results from the single-locus QTDT analysis.
